Equities

Gan & Lee Pharmaceuticals

603087:SHH

Gan & Lee Pharmaceuticals

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)48.42
  • Today's Change-1.26 / -2.54%
  • Shares traded14.16m
  • 1 Year change+0.62%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,6972,2352,540
Total Receivables, Net391203951
Total Inventory861649651
Prepaid expenses718562
Other current assets, total2,1562,4932,666
Total current assets6,1765,6646,870
Property, plant & equipment, net3,9153,7232,778
Goodwill, net------
Intangibles, net1,0911,026872
Long term investments33530231
Note receivable - long term20----
Other long term assets--1452
Total assets11,71510,60710,853
LIABILITIES
Accounts payable1064538
Accrued expenses151153159
Notes payable/short-term debt000
Current portion long-term debt/capital leases2.185.695.07
Other current liabilities, total515609284
Total current liabilities773813486
Total long term debt5.458.3312
Total debt7.621417
Deferred income tax----36
Minority interest0.00(0.16)(0.16)
Other liabilities, total194200152
Total liabilities9731,021686
SHAREHOLDERS EQUITY
Common stock594566562
Additional paid-in capital3,3512,5632,476
Retained earnings (accumulated deficit)6,8656,5257,133
Treasury stock - common(71)(71)--
Unrealized gain (loss)------
Other equity, total3.823.44(3.44)
Total equity10,7439,58610,167
Total liabilities & shareholders' equity11,71510,60710,853
Total common shares outstanding590562562
Treasury shares - common primary issue4.114.110
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.